Background: The study was conducted to compare cycle control, bleeding pattern and efficacy of two low-dose combined oral contraceptives.
Study Design: Four hundred fifty-three women were randomized to receive a 24/4 regimen of drospirenone 3 mg/ethinyl estradiol 20 mcg (drsp 3 mg/EE 20 mcg; n=230) or a 21/7 regimen of desogestrel 150 mcg/EE 20 mcg (DSG 150 mcg/EE 20 mcg; n=223), and recorded bleeding daily over 7 treatment cycles.
Results: The duration [mean 4.7 (SD 1.5)-5.2 (SD 2.2) days in the drsp 3 mg/EE 20 mcg 24/4 group and 5.1 (SD 1.5)-5.4 (SD 2.1) days in the DSG 150 mcg/ EE 20 mcg group] and maximum intensity ("normal bleeding" for >50% of all subjects) of scheduled bleeding in Cycles 1-6 was comparable between treatment groups. The incidence of unscheduled bleeding during Cycles 2-6 was also similar between the two groups (drsp 3 mg/EE 20 mcg, 8.8-17.3%; DSG 150 mcg/ EE 20 mcg, 9.4-16.3%).
Conclusion: Drsp 3 mg/EE 20 mcg 24/4 achieved an acceptable bleeding profile with reliable cycle control, comparable with an established formulation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.contraception.2009.03.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative study on the effects of combined oral contraceptives and dienogest in women with endometriosis‑associated chronic pelvic pain.
Eur J Obstet Gynecol Reprod Biol
January 2025
Department of General Surgery and Medical-Surgical Specialties, Gynaecological Clinic, School of Medicine, University of Catania, Catania, Italy.
Article Synopsis
- The study aimed to compare the pain relief effects of five different combined oral contraceptives (COCs) in women suffering from endometriosis-related chronic pelvic pain, dysmenorrhea, and dyspareunia.
- Conducted between October 2018 and March 2023, the research involved tracking pain levels using a visual analogue scale over 6 months across multiple treatment groups.
- Results indicated that COCs with estradiol (E2) or estetrol (E4) led to significantly better pain relief compared to those with ethinylestradiol (EE), and E2 or E4-containing COCs may be preferable alternatives to dienogest (DNG) for women preferring birth control.
A randomised double-blind trial to determine the bleeding profile of the prolonged-release contraceptive dienogest 2 mg/ethinylestradiol 0.02 mg versus an immediate-release formulation of drospirenone 3 mg/ethinylestradiol 0.02 mg.
Eur J Contracept Reprod Health Care
September 2024
Exeltis Healthcare, Ismaning, Germany.
Background: Dienogest (DNG) 2 mg/ethinylestradiol (EE) 0.02 mg is the first low-dose combined oral contraceptive (COC) with a prolonged-release formulation that allows stable plasma concentrations and has high contraceptive efficacy (Pearl index: 0.2).
View Article and Find Full Text PDFEffects of an oral contraceptive containing estetrol and drospirenone on ovarian function.
Contraception
June 2021
Estetra SRL, an affiliate's company of Mithra Pharmaceuticals, Liège, Belgium; University of Liège, Liège, Belgium.
Objective: To evaluate the effects of estetrol 15 mg/drospirenone 3 mg on ovarian function.
Study Design: Single-center, randomized, open-label, parallel study in healthy young women with proven ovulatory cycles. Participants received either estetrol 15 mg/drospirenone 3 mg (E4/DRSP) (n = 41) or ethinylestradiol 20 µg/drospirenone 3 mg (EE/DRSP) (n = 41) in a 24/4-day regimen for 3 consecutive cycles.
Bleeding Pattern and Management of Unexpected Bleeding/Spotting with an Extended Regimen of a Combination of Ethinylestradiol 20 mcg and Drospirenone 3 mg.
Int J Womens Health
March 2020
Department of Clinical Research, Libbs Farmacêutica Ltda, São Paulo 01140-050, Brazil.
Objective: To compare the bleeding pattern in women using ethinylestradiol 20 mcg/drospirenone 3 mg (EE 20 mcg/DRSP 3 mg) in a 24/4-day cyclic regimen with an extended regimen. Unexpected bleeding/spotting in the extended regimen group was managed by allowing a 4-day hormone-free interval (HFI).
Methods: This was a randomized, prospective, open-label, multicenter study.
Evaluation of different antiandrogenic progestins on clinical and biochemical variables in polycystic ovary syndrome.
Eur J Contracept Reprod Health Care
June 2020
Section of Obstetrics and Gynaecology, Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy.
The aim of the study was to update the results of a previous study published 10 years ago and compare the effect on hyperandrogenism of a newer progestin, dienogest (DNG), in a combined oral contraceptive (COC) formulation with ethinylestradiol (EE), with that of COCs containing the same dose of EE in combination with drospirenone (DRSP) and chlormadinone acetate (CMA). Sixty women with polycystic ovary syndrome (PCOS) aged between 16 and 35 and requiring antiandrogenic contraceptive treatment were randomised to one of three treatment groups: EE 30 µg/DRSP 3 mg, EE 30 µg/CMA 2 mg, EE 30 µg/DNG 2 mg. We evaluated the effects of the three COCs on sex hormone-binding globulin (SHBG) and biochemical markers of hyperandrogenism.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!